Nebula Genomics

LifeVantage Announces Financial Results for the First Quarter of Fiscal 2022

Retrieved on: 
Giovedì, Novembre 4, 2021
Protandim, Adjustment, Share repurchase, Private Securities Litigation Reform Act, Acceleration, Health, SG, Investor relations, Security (finance), EST, Gene, MST, Income, Growth, Nebula Genomics, Depreciation, Earnings, COVID-19, Geography, Research, Dog, Annual report, Table, Optimism, EBITDA, Risk, Sale, Company, U.S. Securities and Exchange Commission, Disclosure, GLOBE, Solution, GAAP, SALT, Oxidative stress, Webcast, Dietary supplement, Hair, Marketing, Skin, Total, Bookkeeping, Video game, Health insurance, Bank

SALT LAKE CITY, Nov. 04, 2021 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN) today reported financial results for its first fiscal quarter ended September 30, 2021.

Key Points: 
  • SALT LAKE CITY, Nov. 04, 2021 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN) today reported financial results for its first fiscal quarter ended September30, 2021.
  • * All comparisons are on a year over year basis and compare the first quarter of fiscal 2022 to the first quarter of fiscal 2021, unless otherwise noted.
  • For the first fiscal quarter, the Company reported revenue of $53.2 million, a 2.9% decrease over the first quarter of fiscal 2021.
  • Operating income for the first quarter of fiscal 2022 was $4.6 million, or 8.7% of revenue, compared to $3.5 million, or 6.4% of revenue, for the first quarter of fiscal 2021.

LifeVantage Appoints Carl Aure as Chief Financial Officer

Retrieved on: 
Lunedì, Ottobre 25, 2021
LLP, Accounting, Research, University, Gene, Industry, Protandim, Market for corporate control, Nebula Genomics, Dog, SALT, Hotel manager, Company, Oxidative stress, KPMG, Growth, Dietary supplement, Skin, Hair, Health, Acquisition, GLOBE, Sale, Certified Public Accountant, Management

SALT LAKE CITY, Oct. 25, 2021 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN) today announced the appointment of Carl Aure as Chief Financial Officer.

Key Points: 
  • SALT LAKE CITY, Oct. 25, 2021 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN) today announced the appointment of Carl Aure as Chief Financial Officer.
  • We are pleased to welcome Carl to the LifeVantage team.
  • His deep financial expertise along with an extensive background in direct selling and international operations make him the ideal candidate to lead all aspects of finance, accounting, tax and treasury, said Steve Fife, President and Chief Executive Officer of LifeVantage.
  • Mr. Aure most recently served as Chief Accounting Officer for New Age, Inc., a social selling company with over 1,100 employees and operations in more than 50 international markets.

ProPhase Labs Provides Business Update

Retrieved on: 
Mercoledì, Ottobre 13, 2021
Risk, Government, Food, Severe acute respiratory syndrome coronavirus 2, TK, Saliva, Private Securities Litigation Reform Act, Nasdaq, Environment, Prophase, Gene, OTC, Dietary supplement, Precision medicine, Nebula, Genomics, Laboratory, Nebula Genomics, SEC, School, Marketing, COVID-19 testing, RSV, DNA, Patient, PCR, CLIA, Failure, COVID, GLOBE, Pharmacy, Â, Company, Chromosome, Polymerase chain reaction, NASDAQ, Research, Acquisition, COVID-19, Pharmaceutical industry, Antibiotics

We are also building a sizable customer base of independent pharmacies that we anticipate will provide consistent and growing testing revenues for our diagnostics business.

Key Points: 
  • We are also building a sizable customer base of independent pharmacies that we anticipate will provide consistent and growing testing revenues for our diagnostics business.
  • In addition, the integration of recently-acquired Nebula Genomics into our ProPhase Precision Medicine division continues to proceed as planned.
  • ProPhase Labs (Nasdaq: PRPH) (ProPhase) is a diversified biotech and genomics company that seeks to leverage its CLIA lab services to provide whole genome sequencing and research direct to consumers and build a genomics data base to be used for further research.
  • ProPhase Labs has decades of experience researching, developing, manufacturing, distributing, marketing, and selling OTC consumer healthcare products and dietary supplements, including dietary supplements under the TK Supplements brand.

Global Nutrigenomics Market Analysis and Forecast Report 2021-2031 - ResearchAndMarkets.com

Retrieved on: 
Lunedì, Agosto 16, 2021
Fitness & Nutrition, Health, Diet, Genetic testing, Nutritional genomics, Industry, Nutritional science, Awareness, Biomarker, Obesity, CAGR, Genome, COVID-19, Factor X, Research, Gene, Health, Investment, Nebula Genomics, Technology, Competitive landscape, Metabolism, Probiotic, Adoption, Dietary supplement, Medical device, Agriculture

The "Global Nutrigenomics Market: Focus on Application, Type, 15 Countries Data, Industry Insights, and Competitive Landscape - Analysis and Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Nutrigenomics Market: Focus on Application, Type, 15 Countries Data, Industry Insights, and Competitive Landscape - Analysis and Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering.
  • The global nutrigenomics market, based on type, is further segmented into the product (dietary usage) and by service (nutrigenomic genetic testing).
  • Based on the application type, which global nutrigenomics market application is anticipated to witness a massive rise in demand during the forecast period 2021-2031?
  • What are the leading trends and consumer preferences witnessed in the global nutrigenomics market?

Nebula Genomics, Partnering with BGI, Sets Industry Standard by Offering 30x Whole-Genome Sequencing for $299

Retrieved on: 
Martedì, Febbraio 18, 2020
Data management, Health, Technology, Genetics, Software, Pharmaceutical, Biotechnology, Branches of biology, Biology, Genetics, Molecular biology, Biotechnology, DNA sequencing, DNA, Whole genome sequencing, Coverage, Genomics, Human genome, Personal genomics, Nebula Genomics, BGI Group

View the full release here: https://www.businesswire.com/news/home/20200218005402/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20200218005402/en/
    Today, most direct-to-consumer genetic tests produce limited information due to the use of outdated technology.
  • In contrast, whole-genome sequencing at 30x coverage accurately reads out over 6 billion letters in the human genome.
  • Nebula Genomics is now excited to offer 30x whole-genome sequencing for $299 a more than a two-fold price reduction.
  • This technology enables Nebula Genomics users to benefit from affordable personal genome sequencing without risking their privacy.